In view of the current complex and changing market situation, taking into account the company's specific situation, and after careful consideration by the company, the company decided to apply to the Shenzhen Stock Exchange to withdraw the application documents for issuing shares to specific targets using simple procedures, and will re-report it in due course according to market conditions. According to the issuance plan (revised draft) previously issued by the company, the number of shares to be issued this time is 248,407.62 million shares, and the total amount of capital to be raised is 156 million yuan. After deducting the issuance fee, all of the net capital raised will be invested in AI-based fully automated thromboelastography system projects, molecular diagnostic blood collection projects, marketing network construction projects, and supplementary liquidity. The distribution targets are Caitong Fund Management Co., Ltd., Nord Fund Management Co., Ltd., Lu Jinxue, Shanghai Langshi Investment Management Center (limited partnership) - Langshi Dingyuan No. 1 Private Equity Investment Fund, and Xue Xiaohua.